Safety, Tolerability, and Pharmacodynamics of ABT ‐122, a Tumor Necrosis Factor– and Interleukin‐17–Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis

ConclusionThe results of these phase I studies suggest that dual neutralization of TNF and IL‐17 with ABT‐122 has characteristics acceptable for further exploration of therapeutic potential in TNF‐ and IL‐17A–driven immune‐mediated inflammatory diseases.

Source: Arthritis and Rheumatism - November 8, 2017 Category: Rheumatology Authors: Roy M. Fleischmann, Frank Wagner, Alan J. Kivitz, Heikki T. Mansikka, Nasser Khan, Ahmed A. Othman, Amit Khatri, Feng Hong, Ping Jiang, Melanie Ruzek, Robert J. Padley Tags: Original Article Source Type: research